This Article Abstract Full Text Full Text (PDF) Erratum (v42,p591) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barst, R. J. Search for Related Content PubMed PubMed Citation Articles by Barst, R. J.

Beraprost therapy for pulmonary arterial hypertension

Robyn J. Barst, MD, FACC^*,*, Michael McGoon, MD, Vallerie McLaughlin, MD, FACC, Victor Tapson, MD, FCCP, Ronald Oudiz, MD, FACC^||, Shelley Shapiro, MD^¶, Ivan M. Robbins, MD^#, Richard Channick, MD^**, David Badesch, MD, Barry K. Rayburn, MD, FACC, Robin Flinchbaugh, BS, Jeff Sigman, BA, Carl Arneson, MStat, Roger Jeffs, PhD Beraprost Study Group

^* Columbia University College of Physicians and Surgeons, New York, New York, USA
Mayo Clinic, Rochester, Minnesota, USA
Rush Presbyterian-St. Luke’s Medical Center, Chicago, Illinois, USA
Duke University Medical Center, Durham, North Carolina, USA
^|| Research and Education Institute at Harbor-UCLA Medical Center, Torrance, California, USA
^¶ USC Medical Center, Los Angeles, California, USA
^# Vanderbilt University Medical Center, Nashville, Tennessee, USA
^** University of California-San Diego Medical Center, La Jolla, California, USA
University of Colorado Health Sciences Center, Denver, Colorado, USA
University of Alabama at Birmingham, Birmingham, Alabama, USA
United Therapeutics Corporation, Research Triangle Park, North Carolina, USA

View larger version (19K): [in a new window]   Figure 1 Median change in 6-min walking distance from baseline to months 3, 6, 9, and 12 in the placebo and beraprost sodium (BPS) groups; p = 0.010 at 3 months; p = 0.016 at 6 months; p = 0.098 at 9 months; and p = 0.180 at 12 months (adjusted for center, etiology, and baseline peak oxygen consumption, 6-min walk, Borg dyspnea score, and vasodilator use). Worst rank for all missing data.

View larger version (16K): [in a new window]   Figure 2 Mean change in Borg dyspnea score from baseline to months 3, 6, 9, and 12 in the placebo and beraprost sodium (BPS) groups; p = 0.24 at 3 months; p = 0.27 at 6 months; p = 0.92 at 9 months; and p = 0.75 at 12 months (analysis of covariance adjusted for center, etiology, and baseline peak oxygen consumption, 6-min walk distance, Borg dyspnea score, and vasodilator use). Black bars = BPS; white bars = placebo. Number in the bars = exact mean rates; lines = standard error of the mean.